Protein & Cell

, Volume 4, Issue 5, pp 331–341

EZH2, an epigenetic driver of prostate cancer


DOI: 10.1007/s13238-013-2093-2

Cite this article as:
Yang, Y.A. & Yu, J. Protein Cell (2013) 4: 331. doi:10.1007/s13238-013-2093-2


The histone methyltransferase EZH2 has been in the limelight of the field of cancer epigenetics for a decade now since it was first discovered to exhibit an elevated expression in metastatic prostate cancer. It persists to attract much scientific attention due to its important role in the process of cancer development and its potential of being an effective therapeutic target. Thus here we review the dysregulation of EZH2 in prostate cancer, its function, upstream regulators, downstream effectors, and current status of EZH2-targeting approaches. This review therefore provides a comprehensive overview of EZH2 in the context of prostate cancer.


EZH2histone methyltransferaseprostate cancerepigenetics
Download to read the full article text

Copyright information

© Higher Education Press and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Division of Hematology/Oncology, Department of MedicineNorthwestern University Feinberg School of MedicineChicagoUSA
  2. 2.Robert H. Lurie Comprehensive Cancer CenterNorthwestern University Feinberg School of MedicineChicagoUSA